AliquantumRx Inc. (AQR) is a Maryland-based biotechnology company developing Cethromycin-HCl, a next-generation macrolide antibiotic for high-impact infectious and biodefense indications. The lead program targets dormant liver-stage malaria, where Cethromycin shows strong potential as both a radical cure for Plasmodium vivax/ovale and a prophylactic against liver-stage P. falciparum. With broad-spectrum activity against Gram-positive, fastidious Gram-negative, and atypical pathogens, it may also address babesiosis, MAI, and anthrax. AQR was founded from a long-standing collaboration and has received early support from Bloomberg Philanthropies, the Gates Foundation, NIH, and TEDCO, with ongoing partnerships with Johns Hopkins Malaria Research Institute and Walter Reed Army Institute of Research.